Strut Health Review: Compounding Safety & Clinical Standards

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Strut Health offers compounded semaglutide and tirzepatide through licensed 503A pharmacies. Evaluating any GLP-1 provider requires understanding compounding standards, licensure verification, and whether personalized biomarker or genetic data inform treatment selection beyond one-size-fits-all protocols.

For patients considering compounded GLP-1 therapy, provider transparency about pharmacy credentials and clinical reasoning matters significantly. PlexusDx prioritizes precision wellness by combining 503A compounding quality with genetic insights that may help contextualize individual medication pathways.

Understanding 503A Compounding Pharmacy Licensing and Standards

Compounded medications are prepared by licensed pharmacies under state and federal oversight. 503A pharmacies compound drugs from bulk chemicals and must comply with USP <797> standards for sterility, potency, and purity. Licensure verification is essential before starting any compounded therapy.

Unlike branded medications manufactured in FDA-inspected facilities, compounded products have less regulatory pre-approval but are legally permitted when prescribed by a licensed provider. Patients should confirm their pharmacy holds current state licensure and follows documented quality protocols.

Comparing Compounding Providers: Key Operational Differences

GLP-1 compounding providers differ in pharmacy partnerships, prescriber oversight, pricing transparency, and whether they incorporate biomarker or genetic assessment. Understanding these distinctions helps patients evaluate fit with their clinical and financial needs.

Some providers use fixed dosing protocols; others adjust based on patient factors. A few integrate genetic testing to contextualize individual peptide pathway predispositions. This framework outlines key operational variables.

Provider Factor	What This Means for Patients
Pharmacy Licensure Verification	Confirm 503A state license and USP <797> compliance; ask for pharmacy name and accreditation details
Prescriber Oversight Model	Licensed MD or NP reviews each patient; dosing protocol flexibility based on individual factors or fixed escalation
Genetic or Biomarker Integration	Optional assessment of peptide pathway predispositions (GLP1R, GIPR, FTO, MC4R variants) to support provider conversation
Pricing Transparency and Monthly Cost	Semaglutide $149/mo; tirzepatide $249/mo; test add-on $99 or standalone $298; no hidden fees disclosed upfront

The Role of Genetic Insights in Personalizing GLP-1 Selection

Recent evidence suggests genetic variants in GLP-1 receptor, GIP receptor, and appetite-regulation pathways may influence individual response patterns to incretin-based therapies. Variants like GLP1R rs6923761 and GIPR rs1800437 are being studied for treatment optimization contexts.

PlexusDx Precision Peptide Genetic Test measures predispositions in these peptide pathways to help providers contextualize why a patient might respond differently to semaglutide versus tirzepatide. Test results should always be interpreted with a qualified healthcare provider, not as predictors of exact outcomes.

Safety, Provider Guidance, and Who Should Use Compounded GLP-1

Compounded GLP-1 medications carry the same clinical considerations as branded formulations: nausea, injection-site reactions, and potential pancreatitis risk in susceptible patients. Pregnancy, personal/family history of medullary thyroid cancer, and multiple endocrine neoplasia type 2 are contraindications requiring careful provider evaluation.

A qualified prescriber should perform baseline metabolic labs, assess medication interactions, and monitor dose tolerance. Genetic insights about peptide pathway variants can support these conversations, but clinical judgment and symptom monitoring remain central to safe, effective treatment.

How PlexusDx Supports a More Personalized Approach

PlexusDx partners exclusively with licensed 503A compounding pharmacies and emphasizes transparency in pharmacy credentials and quality standards. Our genetic testing may help provide context about individual peptide pathway predispositions, supporting a more informed conversation with your prescriber about semaglutide versus tirzepatide selection.

The Precision Peptide Genetic Test reveals predispositions in key GLP-1 and appetite-regulation genes (GLP1R, GIPR, FTO, MC4R). These predispositions reflect biological variance in how your body processes and responds to incretin therapies—not a guarantee of medication response or outcome. Results should be interpreted with a qualified healthcare provider.

Combining genetic insights with rigorous compounding standards and provider oversight can help you make a more personalized treatment decision. Whether you choose PlexusDx or another compounding provider, verify pharmacy licensure, understand the prescriber's clinical reasoning, and discuss any genetic or biomarker data as one input among many.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the difference between a 503A and 503B compounding pharmacy?

503A pharmacies are state-licensed and compound drugs on-demand for individual patients under a prescriber's license. 503B facilities are FDA-registered outsourcing centers that manufacture larger batches. PlexusDx uses only 503A pharmacies.

Are compounded semaglutide and tirzepatide as safe as branded versions?

Compounded formulations must meet USP <797> sterility and potency standards. Safety depends on pharmacy quality control and prescriber oversight. Discuss any concerns about your specific pharmacy with your provider.

How much does PlexusDx compounded GLP-1 cost compared to Strut Health?

PlexusDx compounded semaglutide ranges $149/mo and tirzepatide $249/mo. Exact pricing depends on dose and formulation. Optional genetic testing adds $99 or costs $298 standalone.

Can genetic testing predict how I will respond to a specific GLP-1 medication?

Genetic predispositions may contextualize individual peptide pathway differences but do not predict exact medication response. Results support informed provider conversations; clinical response depends on many factors including metabolism, dose tolerance, and lifestyle.

What peptide genes does the PlexusDx Precision Peptide Genetic Test measure?

The test examines GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 variants to reveal predispositions in appetite regulation and incretin sensitivity. Findings should guide provider discussions, not self-dosing decisions.

Strut Health Review: Compounding Pharmacy Standards and Personalization